These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


314 related items for PubMed ID: 17074014

  • 1. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
    Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH.
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
    Ohishi W, Shirakawa H, Kawakami Y, Kimura S, Kamiyasu M, Tazuma S, Nakanishi T, Chayama K.
    J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM, Kazim SN, Khan LA, Raisuddin S, Parvez MK, Guptan RC, Thakur V, Hasnain SE, Sarin SK.
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [Abstract] [Full Text] [Related]

  • 7. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains.
    Hosseini SY, Sabahi F, Amini-Bavil-Olyaee S, Alavian SM, Merat S.
    J Virol Methods; 2006 Nov; 137(2):298-303. PubMed ID: 16962669
    [Abstract] [Full Text] [Related]

  • 8. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
    Liang WF, Yang DH, Shen YH, Xie YJ, Zhao NF.
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
    Deng H, Lv Y, Fu J.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437
    [Abstract] [Full Text] [Related]

  • 11. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [Abstract] [Full Text] [Related]

  • 12. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN, Chauhan R, Das BC, Sarin SK.
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [Abstract] [Full Text] [Related]

  • 13. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
    Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL.
    Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
    [Abstract] [Full Text] [Related]

  • 14. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
    Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Satoh J, Kobayashi M, Ikeda K, Miyakawa Y, Kumada H.
    J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
    [Abstract] [Full Text] [Related]

  • 15. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
    Natsuizaka M, Hige S, Ono Y, Ogawa K, Nakanishi M, Chuma M, Yoshida S, Asaka M.
    J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
    [Abstract] [Full Text] [Related]

  • 16. Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis.
    Shih YH, Yeh SH, Chen PJ, Chou WP, Wang HY, Liu CJ, Lu SF, Chen DS.
    Antivir Ther; 2008 Mar; 13(4):469-80. PubMed ID: 18672526
    [Abstract] [Full Text] [Related]

  • 17. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C, Ajana F, Canva V, Mouton Y, Yazdanpanah Y, Wattré P, Bocket L.
    Ann Biol Clin (Paris); 2002 Mar; 60(5):581-8. PubMed ID: 12368144
    [Abstract] [Full Text] [Related]

  • 18. [A real-time PCR assay for the quantification of hepatitis B virus DNA and concurrent detection of YMDD motif mutations].
    Ağca H, Sayıner AA, Sengönül A, Simşek I, Akarsu M.
    Mikrobiyol Bul; 2011 Oct; 45(4):664-76. PubMed ID: 22090297
    [Abstract] [Full Text] [Related]

  • 19. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM.
    Antivir Ther; 2006 Oct; 11(4):447-55. PubMed ID: 16856618
    [Abstract] [Full Text] [Related]

  • 20. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.
    Amini-Bavil-Olyaee S, Hosseini SY, Sabahi F, Alavian SM.
    Int J Infect Dis; 2008 Jan; 12(1):83-7. PubMed ID: 17698384
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 16.